Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
PARSIPPANY, N.J. - Zoetis Inc . (NYSE:ZTS), a global leader in animal health, has announced a quarterly dividend of $0.50 per share for the second quarter of 2025. The declared dividend is payable on June 3, 2025, to shareholders of record as of April 21, 2025. According to InvestingPro data, Zoetis has maintained dividend payments for 13 consecutive years and has raised its dividend for 12 consecutive years, demonstrating a strong commitment to shareholder returns.
The company, known for its comprehensive range of products and services to support the health of animals, has a history that spans over seven decades. Zoetis prides itself on contributing to the welfare of animals and, by extension, to the communities that depend on them. With a workforce of approximately 14,100 employees, Zoetis has a presence in over 100 countries and generated revenue of $8.5 billion in the year 2023. The company now commands a market capitalization of $78.7 billion and maintains a strong financial position, earning a "Great" overall health score from InvestingPro, which offers comprehensive analysis through its Pro Research Reports covering 1,400+ top US stocks.
This dividend declaration is part of the company’s ongoing commitment to return value to its shareholders. It follows a consistent pattern of dividend payments, reflecting the company’s stable financial performance and confidence in its business strategy.
Zoetis’s forward-looking statements in the press release indicate their future plans and prospects, including financial performance and dividend payments. However, these statements are subject to various risks and uncertainties that could cause actual results to differ materially from those projected.
Investors are advised that the information contained in this article is based on a press release statement from Zoetis Inc. and should consider the inherent risks detailed in the company’s most recent filings with the SEC when making investment decisions.
Zoetis continues to emphasize its role in nurturing the world through its animal care products, underlining the connection between animal health and human well-being. The company’s dedication to innovation in animal health is evident in its extensive portfolio, which includes medicines, vaccines, diagnostics, and technologies.
The announcement of the dividend is a noteworthy event for investors and stakeholders, reflecting the company’s financial health and its commitment to providing shareholder value. Recent analyst consensus data from InvestingPro shows strong support for the stock, with price targets ranging from $178 to $243 per share. The company maintains healthy fundamentals with a gross profit margin of 70% and operates with a moderate level of debt, though it currently trades at relatively high earnings and EBITDA multiples.
In other recent news, Zoetis Inc. has updated the U.S. label for its canine osteoarthritis pain control product, Librela, following a review of post-approval experiences. Over one million dogs have been treated with Librela since its U.S. launch, and globally, nearly 25 million doses have been distributed. Stifel analysts, in their 2025 Zoetis Outlook report, maintained their Buy rating on Zoetis while adjusting revenue estimates for Librela in the U.S. for 2025 and 2026 downwards.
In addition, Zoetis recently reshaped its leadership, appointing Jamie Brannan as Chief Commercial Officer to enhance the company’s commercial strategy and expand its global market presence. Other leadership changes included the promotion of Keith Sarbaugh to Executive Vice President and Chief Digital & Technology Officer and Jared Shriver to President of U.S. Operations. These recent developments underscore Zoetis’s commitment to growth and innovation in the animal health sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.